Programme overview
Note: the organisation keeps the right to make changes to the programme.
-
08:00
CxO breakfast meeting: Blockchain technology and the impact on the life sciences industry
Hosted by ABN AMRO
Prior to the conference, a breakfast will be held for CEOs, CFOs, COOs and CBOs active in the life sciences sector. Limited places are available and only to MT members from (R&D) life sciences companies who are attending the conference.
-
09:30
Exhibition and Startup corner open
Present your company, products, technology or service. Open from 09:00 till 18:30 hrs.
-
09:45
Hosted by Pivot Park
-
by Mirjam Mol MD, Director Pivot Park
-
Keynote lecture: Mitochondrial drug development; from drawing board to medical applications
by Prof. dr. Jan Smeitink, Professor in Mitochondrial Medicine, founding CEO Khondrion BV, member of the Academia Europaea
Mitochondrial diseases are a clinically heterogeneous group of disorders that arise as a result of dysfunction of the mitochondrial respiratory chain. Prof. dr Jan Smeitink will give an overview on the current status in this emerging field including the known mitochondrial disorders and the drug development programmes. In addition he will address the strategy of his pharmaceutical company Khondrion to treat mitochondrial diseases with innovative drugs.
-
Hosted by Health~Holland
The winner of the Venture Challenge will be announced!
-
11:00
Time for networking and to visit the exhibition and startup corner.
-
11:30
Parallel sessions part 1
1b: E-Health, M-Health and Telemedicine
Hosted by Axon Lawyers
Presentations by:
▪ Anne Bruinvels (Px HealthCare)
1c: Early stage diagnostics and healthcare
Hosted by EP&C
Presentations by:
▪ Jan Groen (MDxHealth B.V.)
-
12:45
Time for networking and to visit the exhibition and startup corner.
-
13:45
Parallel sessions part 2
-
15:00
Time for networking and to visit the exhibition and startup corner.
-
15:45
-
16:20
-
Sebastian Nijman PhD, Founder and Managing Director Scenic Biotech BV
Nijman is co-founder of Scenic Biotech and Associate Professor of the Ludwig Institute for Cancer Research at Oxford University. He will talk about the new venture Scenic Biotech, an international collaboration from Oxford University and the Netherlands Cancer Institute (NKI). The therapeutics spinout company raised €6.5m in Series A financing, which will be used to develop its ‘genetic off-switch’ for cancer and rare genetic diseases. The round was co-led by Netherlands-based life sciences investor BioGeneration Ventures (BGV) and peer INKEF Capital, with the participation of Oxford Sciences Innovation (OSI), the university venturing investor for Oxford University.
-
-
17:00
Drinks, bites and networking
Exhibition and startup corner open -
18:30